This is a routine annual meeting filing with no earnings or operational data. The equity plan amendment adds modest dilution headroom for future grants but has no near-term trading implications. Monitor the next quarterly filing for any guidance updates.
Price Chart
Executive Summary
Globus Medical filed an 8-K reporting that stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing authorized shares by 1,000,000 to a total of 12,000,000 shares. The filing also reports the election of two Class II directors and ratification of Deloitte & Touche as auditor. This is a routine governance filing with no material financial impact.
Key Facts
- Stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing authorized shares by 1,000,000 to a total of 12,000,000 shares of Class A common stock.
- The amendment also increased the aggregate shares available for incentive stock options from 11,000,000 to 12,000,000.
- Keith W. Pfeil and Robert A. Douglas were elected as Class II directors to serve until the 2029 Annual Meeting.
- Deloitte & Touche LLP was ratified as the independent registered public accounting firm for fiscal year 2026.
- Non-binding advisory vote on 2025 named executive officer compensation was approved with approximately 98% of votes cast in favor.
Financial Impact
No financial figures reported. The share increase of 1,000,000 represents approximately 0.9% of total shares outstanding based on a $10.9B market cap, but no immediate dilution or cash impact.
Risk Factors
- Potential future dilution from equity grants under the expanded plan, though the 1,000,000 share increase is small relative to total shares outstanding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-040784 |
| Document: gmed-20260603.htm | 0001628280-26-040784 |
| Document: 0001628280-26-040784-index-headers.html | 0001628280-26-040784 |
| Document: 0001628280-26-040784-index.html | 0001628280-26-040784 |
| Document: 0001628280-26-040784.txt | 0001628280-26-040784 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Institutional Cluster | $81.66 | awaiting T+20 | — | $81.41 (−0.31%) |
Sep 15, 2026 5w ago | 144 | $74.69 $76.32 | ▲ +2.18% | ▼ −0.80% | $81.41 (+9.00%) |
Sep 11, 2026 6w ago | Court Ruling | $75.77 $76.24 | ▲ +0.62% | ▼ −1.64% | $81.41 (+7.44%) |
Aug 26, 2026 8w ago | Press Release | $82.54 $74.16 | ▼ −10.15% | ▼ −10.05% | $81.41 (−1.37%) |
Jul 16, 2026 14w ago | Press Release | $77.00 $85.90 | ▲ +11.56% | ▲ +7.11% | $81.41 (+5.73%) |
Jun 4, 2026 20w ago | 8-K | $80.00 $80.50 | ▲ +0.63% | ▼ −1.24% | $81.41 (+1.76%) |
Jun 4, 2026 20w ago | Court Ruling | $80.00 $80.12 | ▼ −0.15% | ▼ −1.52% | $81.41 (−1.76%) |
Apr 24, 2026 26w ago | DEFA14A | $93.70 $85.10 | ▼ −9.18% | ▼ −14.13% | $81.41 (−13.12%) |
Feb 24, 2026 34w ago | 8-K | $96.22 $87.35 | ▼ −9.22% | ▼ −3.98% | $81.41 (−15.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers